GSK chief scientist and Vir CEO on clinical trial for Covid-19 antibody drug

In this video

Share

GSK chief scientist and Vir CEO on clinical trial for Covid-19 antibody drug

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic. Hal Barron, GlaxoSmithKline’s chief scientific officer, and George Scangos, CEO of Vir Biotechnology, join "Squawk on the Street" to discuss.
05:25
Mon, Aug 31 202010:18 AM EDT